StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for FEED yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-19 | $0.98 | $0.93 | -5.10% | 0.3M |
| 05-20 | $0.94 | $0.93 | -1.03% | 1.2M |
| 05-21 | $0.94 | $0.93 | -1.06% | 0.1M |
| 05-22 | $0.93 | $1.01 | +8.97% | 0.2M |
| 05-26 | $1.03 | $0.93 | -10.15% | 0.2M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
ENvue Medical Inc develops medical devices for enhanced navigation in clinical procedures. The company provides personalized navigation technology to assist clinicians in placing feeding tubes safely and efficiently. Its ENvue system uses smart feeding tubes with sensors, body mapping, and continuous visual guidance to confirm accurate positioning and reduce complications like lung misplacement. The company conducted the business through two primary operating segments: NanoVibronix and ENvue. The firm generates the majority of its revenue from NanoVibronix, which derives revenues from selling its products directly to patients as well as through distributor agreements. ENvue derives revenues from selling its Systems and Nasoenteral tubes.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $653.00K | $2.55M | $2.24M | $1.52M |
Operating Income | $-3.71M | $-22.89M | $-8.07M | $-5.83M |
Net Income | $-3.82M | $-18.18M | $-5.33M | $-5.84M |
EPS (Diluted) | $-6.88 | $-26.69 | $-6.69 | $-8.84 |
Total Assets | $39.87M | $41.12M | $54.38M | $51.48M |
Total Liabilities | $7.86M | $7.63M | $11.92M | $11.01M |
Cash & Equivalents | $2.23M | $4.22M | $6.95M | $4.03M |
Free Cash Flow OCF − CapEx | $-4.33M | $-9.43M | $-6.73M | $-4.74M |
Shares Outstanding | 3.70M | 1.10M | 1.01M | 787.36K |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.